《肿瘤进展的分子机制与泌尿系统癌症的新治疗策略》第二版
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers, 2nd Edition.
作者信息
Ruiz de Porras Vicenç
机构信息
GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
Badalona Applied Research Group in Oncology (B·ARGO), Catalan Institute of Oncology, Camí de les Escoles, s/n, 08916 Badalona, Spain.
出版信息
Int J Mol Sci. 2025 Jul 5;26(13):6496. doi: 10.3390/ijms26136496.
Abstract
Urological cancers, including malignancies of the bladder, kidney, prostate, upper urinary tract, and penis, are among the most common cancers globally [...].
摘要
泌尿系统癌症，包括膀胱癌、肾癌、前列腺癌、上尿路癌和阴茎癌，是全球最常见的癌症之一[...]。
相似文献
1
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers, 2nd Edition.《肿瘤进展的分子机制与泌尿系统癌症的新治疗策略》第二版
Int J Mol Sci. 2025 Jul 5;26(13):6496. doi: 10.3390/ijms26136496.
2
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.肿瘤进展的分子机制和泌尿系统癌症的新治疗策略。
Int J Mol Sci. 2023 Oct 31;24(21):15795. doi: 10.3390/ijms242115795.
3
Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.尿 MicroRNAs 作为泌尿系统癌症的生物标志物：系统评价。
Int J Mol Sci. 2023 Jun 29;24(13):10846. doi: 10.3390/ijms241310846.
4
The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review.曾接受泌尿系统癌症治疗的终末期肾病患者行肾脏移植后肿瘤复发风险：系统评价。
Eur Urol. 2018 Jan;73(1):94-108. doi: 10.1016/j.eururo.2017.07.017. Epub 2017 Aug 10.
5
Epigenetic biomarkers in urological tumors: A systematic review.尿路上皮肿瘤的表观遗传学标志物：系统综述。
Cancer Lett. 2014 Jan 28;342(2):264-74. doi: 10.1016/j.canlet.2011.12.026. Epub 2011 Dec 23.
6
The bibliometric analysis of documents concerning the relationship between the microbiota and urological malignancies.关于微生物群与泌尿生殖系统恶性肿瘤关系的文献计量分析
J Med Microbiol. 2025 Jul;74(7). doi: 10.1099/jmm.0.002041.
7
Association Between Twelve Polymorphisms in Five X-ray Repair Cross-complementing Genes and the Risk of Urological Neoplasms: A Systematic Review and Meta-Analysis.五种 X 射线修复交叉互补基因中的 12 个多态性与泌尿系统肿瘤风险的关联：系统评价和荟萃分析。
EBioMedicine. 2017 Apr;18:94-108. doi: 10.1016/j.ebiom.2017.03.009. Epub 2017 Mar 9.
8
Indocyanine green fluorescence-guided sentinel lymph node identification in urologic cancers: a systematic review and meta-analysis.吲哚菁绿荧光引导下泌尿系统癌症前哨淋巴结的识别：一项系统评价和荟萃分析。
Minerva Urol Nefrol. 2018 Aug;70(4):361-369. doi: 10.23736/S0393-2249.17.02932-0. Epub 2017 Dec 14.
9
[De novo urologic tumors in kidney transplant patients].[肾移植患者的新发泌尿系统肿瘤]
Actas Urol Esp. 2015 Mar;39(2):122-7. doi: 10.1016/j.acuro.2014.05.002. Epub 2014 Jul 2.
10
Predicting outcomes in patients with urologic cancers.预测泌尿系统癌症患者的预后。
Curr Opin Support Palliat Care. 2007 Oct;1(3):153-68. doi: 10.1097/SPC.0b013e3282f125ec.
本文引用的文献
1
Repurposing glucose-lowering drugs for cancer therapy.将降糖药物重新用于癌症治疗。
Trends Cancer. 2025 Jul;11(7):691-710. doi: 10.1016/j.trecan.2025.04.010. Epub 2025 May 15.
2
Tumor-Educated Platelets in Urological Tumors: A Novel Biosource in Liquid Biopsy.泌尿系统肿瘤中的肿瘤衍生血小板：液体活检中的新型生物来源
Int J Mol Sci. 2025 Apr 11;26(8):3595. doi: 10.3390/ijms26083595.
3
Tumor-educated platelet, a potential liquid biopsy biosource in pancreatic cancer: A review.肿瘤驯化血小板：胰腺癌潜在的液体活检生物源综述
Pathol Res Pract. 2025 Jun;270:155986. doi: 10.1016/j.prp.2025.155986. Epub 2025 Apr 21.
4
Repurposing of Metabolic Drugs Metformin and Simvastatin as an Emerging Class of Cancer Therapeutics.将代谢药物二甲双胍和辛伐他汀重新用作一类新兴的癌症治疗药物。
Pharm Res. 2025 Jan;42(1):49-67. doi: 10.1007/s11095-024-03811-1. Epub 2025 Jan 7.
5
Liquid biopsy in cancer current: status, challenges and future prospects.癌症液体活检的现状、挑战与未来前景
Signal Transduct Target Ther. 2024 Dec 2;9(1):336. doi: 10.1038/s41392-024-02021-w.
6
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.泌尿系统肿瘤的不断变化的分子谱和可操作的改变。
Curr Oncol. 2024 Nov 6;31(11):6909-6937. doi: 10.3390/curroncol31110511.
7
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.重新利用代谢调节剂：抗糖尿病药物作为抗癌剂。
Mol Biomed. 2024 Sep 28;5(1):40. doi: 10.1186/s43556-024-00204-z.
8
MMP-14 Exhibits Greater Expression, Content and Activity Compared to MMP-15 in Human Renal Carcinoma.MMP-14 在人类肾细胞癌中的表达、含量和活性均高于 MMP-15。
Int J Mol Sci. 2024 Jul 25;25(15):8107. doi: 10.3390/ijms25158107.
9
Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.在实体瘤中扩增频繁，并预测转移性尿路上皮癌对恩福妥单抗 Vedotin 的反应。
J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24.
10
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
Zotero 插件